Novartis and Medicines for Malaria Venture reported positive Phase III results for GanLum, a next‑generation antimalarial combining ganaplacide with lumefantrine. The KALUMA trial across 34 sites in 12 African countries achieved a 97.4% cure rate for uncomplicated P. falciparum malaria, outperforming the comparator (94%). Ganaplacide targets the parasite’s intracellular secretory pathway and represents a new mechanism of action. Investigators framed GanLum as a strategic tool to counteract emerging artemisinin resistance in endemic regions. The dataset supports regulatory submissions and potential WHO policy discussions; public‑health groups emphasized the need for manufacturing scaleup and access planning if approvals proceed.